Full Breakdown
Incyte's Minjuvi Approved in Japan for Follicular Lymphoma Treatment
12/23/2025, 6:07:45 AM
Approval Announcement and Significance
Incyte Biosciences Japan G.K. has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide. This treatment is designated for adult patients with relapsed or refractory follicular lymphoma (FL), marking a significant milestone as it represents the first dual-targeted immunotherapy combination for this condition in Japan. Yasuyuki Ishida, General Manager of Incyte Biosciences Japan, emphasized that this approval provides a chemotherapy-free option that improves progression-free survival for eligible patients.
Clinical Trial and Efficacy
The approval is based on the pivotal Phase 3 inMIND trial, which involved 654 adult participants, including those from Japan. The study demonstrated that the combination of Minjuvi, rituximab, and lenalidomide significantly improved progression-free survival (PFS) compared to the control group. Patients receiving Minjuvi achieved a median PFS of 22.4 months, in contrast to 13.9 months in the control arm, with a hazard ratio of 0.43 indicating a substantial reduction in the risk of disease progression.
Background on Follicular Lymphoma
Follicular lymphoma is the second most common form of B-cell non-Hodgkin lymphoma in Japan, accounting for 13.5% of all NHL cases. It is considered incurable, with approximately 20% of patients experiencing progression or relapse within the first two years of treatment. This early progression is associated with a significantly poorer prognosis, highlighting the unmet need for effective treatment options for relapsed or refractory FL.
Official Statements & Responses
Incyte's announcement reflects its commitment to addressing critical treatment gaps for patients with challenging diseases. The company noted that the inMIND study is a global, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of tafasitamab in combination with rituximab and lenalidomide. The primary endpoint is progression-free survival, with key secondary endpoints including overall survival and complete response rates.
Criticism & Opposition
While the approval is a positive development, some experts caution that ongoing research and further clinical trials are necessary to fully understand the long-term efficacy and safety of this treatment combination. Concerns remain regarding the potential for adverse reactions and the need for comprehensive post-marketing surveillance.
Verbatim Quotes
- “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” — Yasuyuki Ishida, General Manager, Incyte Biosciences Japan
- “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease.” — Yasuyuki Ishida, General Manager, Incyte Biosciences Japan
What's Next
Following this approval, Incyte plans to monitor the treatment's uptake in clinical practice and continue research to further validate the findings from the inMIND trial. The company remains committed to addressing the needs of patients with relapsed or refractory follicular lymphoma and exploring additional therapeutic options.
